Evidence map›Paper›PMID 36638942›Full record

ArticleActa biomaterialia2023

MicroRNA-based engineering of mesenchymal stem cell extracellular vesicles for treatment of retinal ischemic disorders: Engineered extracellular vesiclesand retinal ischemia.

Biji Mathew, Lorea Gamboa Acha, Leianne A Torres, Chun-Chieh Huang, Alice Liu, Sergey Kalinin, Kasey Leung, Yang Dai, Douglas L Feinstein, Sriram Ravindran and 1 more

Open access · greenAbstract read
In one paragraph

Article in Acta biomaterialia, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed
6.0field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 39 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Article
  8. Review
  9. Review
  10. Rekindling Vision: Innovative Strategies for Treating Retinal Degeneration.International journal of molecular sciences · 2025
    Review
  11. Review
  12. Review
  13. Review
  14. Review
  15. Article
  16. Review
  17. Review
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Biji MathewDepartment of Anesthesiology, College of Medicine, University of Illinois-Chicago.
Lorea Gamboa AchaDepartment of Anesthesiology, College of Medicine, University of Illinois-Chicago.
Leianne A TorresDepartment of Anesthesiology, College of Medicine, University of Illinois-Chicago.
Chun-Chieh HuangDepartment of Oral Biology, College of Dentistry, University of Illinois-Chicago.
Alice LiuDepartment of Anesthesiology, College of Medicine, University of Illinois-Chicago.
Sergey KalininDepartment of Anesthesiology, College of Medicine, University of Illinois-Chicago.
Kasey LeungDepartment of Oral Biology, College of Dentistry, University of Illinois-Chicago.
Yang DaiDepartment of Bioengineering, College of Engineering, University of Illinois-Chicago.
Douglas L FeinsteinDepartment of Anesthesiology, College of Medicine, University of Illinois-Chicago; Jesse Brown Veterans Affairs, Chicago, IL.
Sriram RavindranDepartment of Oral Biology, College of Dentistry, University of Illinois-Chicago. Electronic address: sravin1@uic.edu.
Steven RothDepartment of Anesthesiology, College of Medicine, University of Illinois-Chicago. Electronic address: rothgas@uic.edu.
University of Illinois Chicago · USIllinois College · US

Funding

Strengthening Stakeholder Engagement in Human Research Protections.UL1TR002003 · NCATS · UNIVERSITY OF ILLINOIS AT CHICAGO · PI KARNIK, NIRANJAN SUBHASH, MERMELSTEIN, ROBIN J. · 2016 to 2024
$33.7M
Translational Core for Therapeutic and Diagnostic DevelopmentP30EY001792 · NEI · UNIVERSITY OF ILLINOIS AT CHICAGO · PI MCANANY, JAMES JASON · 1985 to 2025
$14.8M
3D Encapsulation, Bioprinting and Controlled Delivery of Functionally Engineered EVs (FEEs)R01DE030495 · NIDCR · UNIVERSITY OF ILLINOIS AT CHICAGO · PI COOPER, LYNDON F, GAJENDRAREDDY, PRAVEEN · 2021 to 2025
$2.3M
Mesenchymal stem cell extracellular vesicles for ischemic retinal damageR01EY033902 · NEI · UNIVERSITY OF ILLINOIS AT CHICAGO · PI STEVEN ROTH, Sriram Ravindran · 2022 to 2026
$2.1M
Functional Activation and Targeting of Exosomes for Regenerative MedicineR01DE027404 · NIDCR · UNIVERSITY OF ILLINOIS AT CHICAGO · PI GAJENDRAREDDY, PRAVEEN, RAVINDRAN, SRIRAM · 2018 to 2022
$2.1M
VRC: Engineered extracellular vesicles for mild TBI-induced retinal injuryR01EY034716 · NEI · UNIVERSITY OF ILLINOIS AT CHICAGO · PI ROTH, STEVEN · 2022 to 2024
$968k
Novel Cell Free Therapy for GlaucomaR21EY028690 · NEI · UNIVERSITY OF ILLINOIS AT CHICAGO · PI ROTH, STEVEN · 2019 to 2020
$477k
Liver Kinase B1, a genetic risk factor for multiple sclerosisI01BX002625 · VA · JESSE BROWN VA MEDICAL CENTER · PI FEINSTEIN, DOUGLAS L. · 2016 to 2023
–
BLR&D Research Career Scientist Award ApplicationIK6BX004852 · VA · JESSE BROWN VA MEDICAL CENTER · PI Douglas L. Feinstein · 2020 to 2026
–
BLRD VA I01 BX002625BLRD VA IK6 BX004852NCATS NIH HHS UL1 TR002003NEI NIH HHS P30 EY001792NEI NIH HHS R01 EY033902NEI NIH HHS R01 EY034716NEI NIH HHS R21 EY028690NIDCR NIH HHS R01 DE027404NIDCR NIH HHS R01 DE030495
6 · The paper itself

Abstract

Mesenchymal stem cell (MSCs)-derived extracellular vesicles (EVs) are emerging therapeutic tools. Hypoxic pre-conditioning (HPC) of MSCs altered the production of microRNAs (miRNAs) in EVs, and enhanced the cytoprotective, anti-inflammatory, and neuroprotective properties of their derivative EVs in retinal cells. EV miRNAs were identified as the primary contributors of these EV functions. Through miRNA seq analyses, miRNA-424 was identified as a candidate for the retina to overexpress in EVs for enhancing cytoprotection and anti-inflammatory effects. FEEs (functionally engineered EVs) overexpressing miR424 (FEE424) significantly enhanced neuroprotection and anti-inflammatory activities in vitro in retinal cells. FEE424 functioned by reducing inflammatory cytokine production in retinal microglia, and attenuating oxygen free radicals in retinal Muller cells and microvascular endothelial cells, providing a multi-pronged approach to enhancing recovery after retinal ischemic insult. In an in vivo model of retinal ischemia, native, HPC, and FEE424 MSC EVs robustly and similarly restored function to close to baseline, and prevented loss of retinal ganglion cells, but HPC EVs provided the most effective attenuation of apoptosis-related and inflammatory cytokine gene expression. These results indicate the potential for EV engineering to produce ameliorative effects for retinal diseases with a significant inflammatory component. STATEMENT OF SIGNIFICANCE: We show that functionally engineered extracellular vesicles (FEEs) from mesenchymal stem cells (MSCs) provide cytoprotection in rat retina subjected to ischemia. FEEs overexpressing microRNA 424 (FEE424) function by reducing inflammatory cytokine production in retinal microglia, and attenuating oxygen free radicals in Muller cells and microvascular endothelial cells, providing a multi-pronged approach to enhancing recovery. In an in vivo model of retinal ischemia in rats, native, hypoxic-preconditioned (HPC), and FEE424 MSC EVs robustly and similarly restored function, and prevented loss of retinal ganglion cells, but HPC EVs provided the most effective attenuation of apoptosis-related and inflammatory cytokine gene expression. The results indicate the potential for EV engineering to produce ameliorative effects for retinal diseases with a significant inflammatory component.

Indexed as

Extracellular VesiclesMesenchymal Stem CellsMicroRNAsRetinal DiseasesAnimalsAnti-Inflammatory AgentsCytokinesEndothelial CellsHypoxiaIschemiaRatsAnti-Inflammatory AgentsCytokinesMicroRNAsExtracellular vesiclesHypoxic preconditioningInflammationIschemiaMesenchymal stem cellsMicrogliaMicroRNARetinal ganglion cells

Identifiers

PMID36638942
PMCPMC10005109
OpenAlexW4316174706

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.